These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 21098485)

  • 1. In vitro selection and characterization of HIV-1 variants with increased resistance to sifuvirtide, a novel HIV-1 fusion inhibitor.
    Liu Z; Shan M; Li L; Lu L; Meng S; Chen C; He Y; Jiang S; Zhang L
    J Biol Chem; 2011 Feb; 286(5):3277-87. PubMed ID: 21098485
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mechanism of HIV-1 Resistance to Short-Peptide Fusion Inhibitors Targeting the Gp41 Pocket.
    Su Y; Chong H; Qiu Z; Xiong S; He Y
    J Virol; 2015 Jun; 89(11):5801-11. PubMed ID: 25787278
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mechanism of HIV-1 Resistance to an Electronically Constrained α-Helical Peptide Membrane Fusion Inhibitor.
    Wu X; Liu Z; Ding X; Yu D; Wei H; Qin B; Zhu Y; Chong H; Cui S; He Y
    J Virol; 2018 Apr; 92(7):. PubMed ID: 29321334
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular mechanism of HIV-1 resistance to sifuvirtide, a clinical trial-approved membrane fusion inhibitor.
    Yu D; Ding X; Liu Z; Wu X; Zhu Y; Wei H; Chong H; Cui S; He Y
    J Biol Chem; 2018 Aug; 293(33):12703-12718. PubMed ID: 29929981
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of human immunodeficiency virus type 1 gp41 amino acid substitutions selected during enfuvirtide treatment on gp41 binding and antiviral potency of enfuvirtide in vitro.
    Mink M; Mosier SM; Janumpalli S; Davison D; Jin L; Melby T; Sista P; Erickson J; Lambert D; Stanfield-Oakley SA; Salgo M; Cammack N; Matthews T; Greenberg ML
    J Virol; 2005 Oct; 79(19):12447-54. PubMed ID: 16160172
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The M-T hook structure increases the potency of HIV-1 fusion inhibitor sifuvirtide and overcomes drug resistance.
    Chong H; Yao X; Qiu Z; Sun J; Qiao Y; Zhang M; Wang M; Cui S; He Y
    J Antimicrob Chemother; 2014 Oct; 69(10):2759-69. PubMed ID: 24908047
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synergistic efficacy of combination of enfuvirtide and sifuvirtide, the first- and next-generation HIV-fusion inhibitors.
    Pan C; Lu H; Qi Z; Jiang S
    AIDS; 2009 Mar; 23(5):639-41. PubMed ID: 19242316
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genetic Pathway of HIV-1 Resistance to Novel Fusion Inhibitors Targeting the Gp41 Pocket.
    Su Y; Chong H; Xiong S; Qiao Y; Qiu Z; He Y
    J Virol; 2015 Dec; 89(24):12467-79. PubMed ID: 26446597
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design of peptide-based inhibitors for human immunodeficiency virus type 1 strains resistant to T-20.
    Izumi K; Kodama E; Shimura K; Sakagami Y; Watanabe K; Ito S; Watabe T; Terakawa Y; Nishikawa H; Sarafianos SG; Kitaura K; Oishi S; Fujii N; Matsuoka M
    J Biol Chem; 2009 Feb; 284(8):4914-20. PubMed ID: 19073606
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Selection of T1249-resistant human immunodeficiency virus type 1 variants.
    Eggink D; Baldwin CE; Deng Y; Langedijk JP; Lu M; Sanders RW; Berkhout B
    J Virol; 2008 Jul; 82(13):6678-88. PubMed ID: 18434391
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mechanism of resistance to S138A substituted enfuvirtide and its application to peptide design.
    Izumi K; Kawaji K; Miyamoto F; Shimane K; Shimura K; Sakagami Y; Hattori T; Watanabe K; Oishi S; Fujii N; Matsuoka M; Kaku M; Sarafianos SG; Kodama EN
    Int J Biochem Cell Biol; 2013 Apr; 45(4):908-15. PubMed ID: 23357451
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of HIV-1 resistance to a fusion inhibitor, N36, derived from the gp41 amino-terminal heptad repeat.
    Izumi K; Nakamura S; Nakano H; Shimura K; Sakagami Y; Oishi S; Uchiyama S; Ohkubo T; Kobayashi Y; Fujii N; Matsuoka M; Kodama EN
    Antiviral Res; 2010 Aug; 87(2):179-86. PubMed ID: 20438763
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The improved efficacy of Sifuvirtide compared with enfuvirtide might be related to its selectivity for the rigid biomembrane, as determined through surface plasmon resonance.
    Cao P; Dou G; Cheng Y; Che J
    PLoS One; 2017; 12(2):e0171567. PubMed ID: 28207776
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genotypic changes in human immunodeficiency virus type 1 envelope glycoproteins on treatment with the fusion inhibitor enfuvirtide and their influence on changes in drug susceptibility in vitro.
    Su C; Melby T; DeMasi R; Ravindran P; Heilek-Snyder G
    J Clin Virol; 2006 Aug; 36(4):249-57. PubMed ID: 16765082
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SC29EK, a peptide fusion inhibitor with enhanced alpha-helicity, inhibits replication of human immunodeficiency virus type 1 mutants resistant to enfuvirtide.
    Naito T; Izumi K; Kodama E; Sakagami Y; Kajiwara K; Nishikawa H; Watanabe K; Sarafianos SG; Oishi S; Fujii N; Matsuoka M
    Antimicrob Agents Chemother; 2009 Mar; 53(3):1013-8. PubMed ID: 19114674
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The rare HIV-1 gp41 mutations 43T and 50V elevate enfuvirtide resistance levels of common enfuvirtide resistance mutations that did not impact susceptibility to sifuvirtide.
    Covens K; Megens S; Dekeersmaeker N; Kabeya K; Balzarini J; De Wit S; Vandamme AM; Van Laethem K
    Antiviral Res; 2010 Jun; 86(3):253-60. PubMed ID: 20227441
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Resistance and replicative capacity of HIV-1 strains selected in vivo by long-term enfuvirtide treatment.
    Menzo S; Castagna A; Monachetti A; Hasson H; Danise A; Carini E; Bagnarelli P; Lazzarin A; Clementi M
    New Microbiol; 2004 Apr; 27(2 Suppl 1):51-61. PubMed ID: 15646065
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Heptad-repeat-2 mutations enhance the stability of the enfuvirtide-resistant HIV-1 gp41 hairpin structure.
    Jenwitheesuk E; Samudrala R
    Antivir Ther; 2005; 10(8):893-900. PubMed ID: 16430194
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Helical Short-Peptide Fusion Inhibitor with Highly Potent Activity against Human Immunodeficiency Virus Type 1 (HIV-1), HIV-2, and Simian Immunodeficiency Virus.
    Xiong S; Borrego P; Ding X; Zhu Y; Martins A; Chong H; Taveira N; He Y
    J Virol; 2017 Jan; 91(1):. PubMed ID: 27795437
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relative replicative fitness of human immunodeficiency virus type 1 mutants resistant to enfuvirtide (T-20).
    Lu J; Sista P; Giguel F; Greenberg M; Kuritzkes DR
    J Virol; 2004 May; 78(9):4628-37. PubMed ID: 15078945
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.